Vaspin serum concentration in patients with type 2 diabetes and carotid plaque

Journal of International Medical Research

Volumn 40, Issue 5, 2012, Pages 1670-1676

  Li, Z ^a   Ma, C ^a   Li, L ^b   Pan, X ^a   Chen, Li ^c  

^a GUANGZHOU RED CROSS HOSPITAL   (China)

^b TAIAN CITY CENTRAL HOSPITAL   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Carotid plaque; Type 2 diabetes; Vaspin

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VASPIN; SERINE PROTEINASE INHIBITOR; SERPINA12 PROTEIN, HUMAN;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILY HISTORY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; SMOKING HABIT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO; AGED; ATHEROSCLEROSIS; BLOOD; CAROTID ARTERY DISEASE; CASE CONTROL STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; RISK FACTOR; STATISTICAL MODEL;

AGED; ATHEROSCLEROSIS; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; SERPINS;

EID: 84880617446     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/030006051204000506     Document Type: Article

References (26)

1. Haffner SM, Lehto S, Rönnemaa T, et al: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–234.
2. Kopelman PG: Obesity as a medical problem. Nature 2000; 404: 635–643.
3. Mohamed-Ali V, Pinkney JH, Coppack SW: Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 1998; 22: 1145–1158.
4. Ohlson LO, Larsson B, Svärdsudd K, et al: The influence of body fat distribution on the incidence of diabetes mellitus: 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes 1985; 34: 1055–1058.
5. Kissebah AH, Krakower GR: Regional adiposity and morbidity. Physiol Rev 1994; 74: 761–811.
6. Williams MJ, Hunter GR, Kekes-Szabo T, et al: Intra-abdominal adipose tissue cut-points related to elevated cardiovascular risk in women. Int J Obes Relat Metab Disord 1996; 20: 613–617.
7. Fontana L, Eagon JC, Trujillo ME, et al: Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007; 56: 1010–1013.
8. Curat CA, Wegner V, Sengenès C, et al: Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006; 49: 744–747.
9. Hida K, Wada J, Eguchi J, et al: Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A 2005; 102: 10610–10615.
10. Klöting N, Berndt J, Kralisch S, et al: Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 2006; 339: 430–436.
11. Seeger J, Ziegelmeier M, Bachmann A, et al: Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J Clin Endocrinol Metab 2008; 93: 247–251.
12. Gulcelik NE, Karakaya J, Gedik A, et al: Serum vaspin levels in type 2 diabetic women in relation to microvascular complications. Eur J Endocrinol 2009; 160: 65–70.
13. Puavilai G, Chanprasertyotin S, Sriphrapradaeng A: Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. World Health Organization. Diabetes Res Clin Pract 1999; 44: 21–26.
14. Matthews DR, Hosker JP, Rudenski AS, et al: Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.
15. Stout RW: Insulin and atheroma. 20-yr perspective. Diabetes Care 1990; 13: 631–654.
16. Kawamoto R, Kajiwara T, Oka Y, et al: Association between abdominal wall fat index and carotid atherosclerosis in women. J Atheroscler Thromb 2002; 9: 213–218.
17. Zimmet P, Boyko EJ, Collier GR, et al: Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. Ann N Y Acad Sci 1999; 892: 25–44.
18. Ronti T, Lupattelli G, Mannarino E: The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf) 2006; 64: 355–365.
19. Avogaro A, de Kreutzenberg SV, Fadini G: Endothelial dysfunction: causes and consequences in patients with diabetes mellitus. Diabetes Res Clin Pract 2008; 82(suppl 2): S94–S101.
20. Lago F, Dieguez C, Gómez-Reino J, et al: The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 2007; 18: 313–325.
21. Youn BS, Klöting N, Kratzsch J, et al: Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008; 57: 372–377.
22. Kim SM, Cho GJ, Yannakoulia M, et al: Lifestyle modification increases circulating adiponectin concentrations but does not change vaspin concentrations. Metabolism 2011; 60: 1294–1299.
23. Aust G, Richter O, Rohm S, et al: Vaspin serum concentrations in patients with carotid stenosis. Atherosclerosis 2009; 204: 262–266.
24. Kadoglou NP, Gkontopoulos A, Kapelouzou A, et al: Serum levels of vaspin and visfatin in patients with coronary artery disease–Kozani study. Clin Chim Acta 2011; 412: 48–52.
25. Kobat MA, Celik A, Balin M, et al: The investigation of serum vaspin level in atherosclerotic coronary artery disease. J Clin Med Res 2012; 4: 110–113.
26. Harris MI, Klein R, Welborn TA, et al: Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diabetes Care 1992; 15: 815–819.